-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – psilocybin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry psilocybin Drug Details Psilocybin (TRP-8802) is under development for the treatment of fibromyalgia, binge...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NYPRG-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NYPRG-101 Drug Details NYPRG-101 (BOL-148) is under development for the treatment of migraine, cluster...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – psilocybin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry psilocybin Drug Details Psilocybin is under development for the treatment of substance abuse disorder,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – psilocybin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry psilocybin Drug Details Psilocybin is under development for the treatment of treatment-resistant depressive disorder...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – psilocybin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry psilocybin Drug Details Psilocybin is under investigation for the treatment of obsessive compulsive disorder,...
-
Product Insights
Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity. The Migraine pipeline drugs market research report provides comprehensive information on the therapeutics...
-
Product Insights
Opium (Opioid) Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Opium (Opioid) Addiction develops after using opioids regularly for a period. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). Its signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping, and pain in the bones. The predisposing factors include age, personal history/ family history of substance abuse, cigarette dependency, and psychological stress. The Opium...
-
Product Insights
Depression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Its signs and symptoms include sleep disturbances, including insomnia or sleeping too much, appetite changes, anxiety, agitation, or restlessness, and physical problems like back pain or headaches. Depression can be treated via antidepressants, mood stabilizers, or antipsychotics. The Depression pipeline market research report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of...
-
Product Insights
Cluster Headache Syndrome (Cluster Headache) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cluster headache is pain that occurs along one side of the head. It frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing, and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans. The Cluster Headache Syndrome (Cluster Headache) Drugs in Development market research report provides an overview of the Cluster Headache Syndrome (Cluster Headache) pipeline landscape. The report provides comprehensive information on the...
-
Product Insights
Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Alcohol Addiction pipeline market research report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcohol Addiction and features dormant...